Company / Shareholders' Equity
Oric Pharmaceuticals, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$384.4M
FY2025
5-year range
$222.4M / $384.4M
FY2021-FY2025
Trend
+58.1%
vs FY2024
Sector context
#110 of 213
Health Care
What the data says
At $384M, Oric Pharmaceuticals, Inc.'s shareholders' equity ranks #110 of 213 in the Health Care sector. Shareholders' Equity has increased for 3 consecutive years, from $222M in FY2022 to $384M in FY2025.
Based on SEC 10-K filings.
$384M in FY2025 with a 5-year CAGR of +5.8%.
Improved from $224M to $384M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +20.0%
- 5-Year CAGR
- +5.8%
- 10-Year CAGR
- -
Sector benchmark
#110 of 213 in Health CareTop 52% of 213This company $384.4M Sector average $2.5B
▼
-84.9% below sector average
Key checks
Key Insights
- Oric Pharmaceuticals, Inc.'s shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +5.8%, indicating consistent growth.
- In FY2025, shareholders' equity increased 58.1% year-over-year.
- Ranks #110 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 5.96 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $384.4M | +58.1% |
| FY2024 | $243.1M | +8.5% |
| FY2023 | $224.1M | +0.8% |
| FY2022 | $222.4M | -18.5% |
| FY2021 | $273.0M | -5.8% |
| FY2020 | $289.8M | +421.7% |
| FY2019 | -$90.1M | -39.8% |
| FY2018 | -$64.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026